Australia markets closed

Mersana Therapeutics, Inc. (MRSN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.4000-0.1250 (-3.55%)
At close: 04:00PM EDT
3.4999 +0.10 (+2.94%)
Pre-market: 08:31AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.5250
Open3.4600
Bid3.3800 x 200
Ask3.4500 x 400
Day's range3.3200 - 3.5250
52-week range0.8010 - 9.6200
Volume876,310
Avg. volume2,144,500
Market cap416.027M
Beta (5Y monthly)1.59
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

    Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024Patient recruitment ongoing in Phase 1 clinical trial of XMT-2056; plan to advance dose escalation in 2024 Continue to expect capital resources will support current operating plan commitments into 2026Conference call today at 8:00 a.m. ET CAMBRIDGE, Mas

  • GlobeNewswire

    Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on May 1, 2024, an authorized sub-committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit (RSU) award to acquire 35,100 shares of its common stock

  • GlobeNewswire

    Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024

    CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the first quarter ended March 31, 2024 on Thursday, May 9, 2024. The company will host a conference call and webcast at 8:00 a.m. Eas